oral semaglutide cardiovascular benefit soul trial outcomes soul trial results Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes Oral semaglutide found to lower

GLP-1 medications, including well-known options like Ozempic, Wegovy and Zepbound, help people manage their weight and conditions like type 2 diabetes by slowing digestion, reducing appetite and supporting blood sugar control

Despite its performance-oriented interest, it has not undergone full clinical approval and is primarily studied as a research compound

Important notice: Lipo-C is compounded and not FDA-approved

The minute-long ad from telehealth company Hims & Hers shows imagery including a scale, food including pies and cheeseburgers, and a refrigerator full of vials of Hims & Hers-labeled medications alongside narration about the state of America's obesity crisis